210 articles
AYUSH-SL
AYUSH-SL is a CCRAS coded poly-herbal Ayurvedic formulation for lymphatic filariasis (Shlipada), tested in a 180-participant double-blind placebo-controlled trial with MDA for filarial lymphedema.
Baloxavir marboxil
Baloxavir marboxil (Xofluza), a single-dose oral influenza PA endonuclease inhibitor developed by Shionogi with Roche, approved in Japan in 2018 and the US in 2018 for treatment and post-exposure prophylaxis in people 5 years and older, with PA I38 resistance as its main limitation.
Beclabuvir
Beclabuvir (BMS-791325), a non-nucleoside allosteric inhibitor of HCV NS5B polymerase (Thumb 1 site), developed by Bristol-Myers Squibb; approved in Japan as Ximency with daclatasvir and asunaprevir for genotype 1 hepatitis C.
Bemnifosbuvir
Bemnifosbuvir (AT-527, RO7496998) is an oral guanosine nucleotide analogue prodrug of AT-9010, a viral RNA polymerase inhibitor developed by Atea Pharmaceuticals for hepatitis C and, unsuccessfully, COVID-19; now Phase 3 with ruzasvir for HCV.
Bepirovirsen
Bepirovirsen, marketed in Japan as Hibsago, is a GSK and Ionis antisense oligonucleotide that targets hepatitis B virus RNA, approved in Japan in 2026 for chronic hepatitis B.
Berdazimer sodium
Berdazimer sodium (ZELSUVMI) is a polymeric nitric oxide-releasing topical gel, 10.3%, FDA-approved January 5, 2024 for molluscum contagiosum in patients 1 year and older; applied once daily for 12 weeks, it cleared lesions in 32.4% versus 19.7% with vehicle in B-SIMPLE4.
Bictegravir
Bictegravir (BIC), a Gilead HIV-1 integrase strand transfer inhibitor coformulated with emtricitabine and tenofovir alafenamide as Biktarvy, FDA-approved February 7, 2018; once-daily 50/200/25 mg single-tablet regimen with high resistance barrier.
Bifonazole
Bifonazole (Canespor, Mycospor) is a halogen-free imidazole topical antifungal, ATC D01AC10, marketed since 1982. Its 1% cream, gel, solution, and powder are applied once daily for dermatophytoses, cutaneous candidiasis, and pityriasis versicolor.
Bithionol
Bithionol (Bitin, Actamer), a chlorinated bisphenol anthelmintic, treated Fasciola, Paragonimus, and tapeworm infections before photosensitivity led to its 1967 FDA withdrawal; now obsolete as a drug but studied for antibacterial and anticancer repurposing.
Boceprevir
Boceprevir (Victrelis, SCH 503034), an HCV NS3/4A protease inhibitor approved by the FDA in 2011 with telaprevir for genotype 1 hepatitis C; now replaced by interferon-free oral DAAs.
Brincidofovir
Brincidofovir (Tembexa, CMX001), a lipid conjugate of cidofovir, is an oral orthopoxvirus DNA polymerase inhibitor FDA-approved June 2021 to treat smallpox under the Animal Rule; not approved for mpox.
Broxyquinoline
Broxyquinoline (5,7-dibromo-8-hydroxyquinoline; dibromoxin, Starogyn) is a withdrawn halogenated 8-hydroxyquinoline amebicide with ATC codes P01AA01, G01AC06, and A07AX01, now studied as an antimicrobial adjuvant.
Bulaquine (Elubaquin)
Bulaquine (elubaquine, CDRI 80/53) is an Indian 8-aminoquinoline anti-relapse antimalarial for Plasmodium vivax, a primaquine analogue and prodrug marketed as Aablaquine with chloroquine; development discontinued.
Bulevirtide
Bulevirtide (Hepcludex, formerly Myrcludex B) is a first-in-class 47-amino-acid lipopeptide entry inhibitor blocking the NTCP receptor used by hepatitis D and B viruses. Approved by EMA in 2020 and FDA in 2026 for chronic hepatitis D with compensated liver disease; 2 mg daily subcutaneous injection.
Butenafine
Butenafine is a synthetic topical antifungal drug, the first and only benzylamine, used as a 1% cream for athlete's foot, ringworm, jock itch, and tinea versicolor since 1996.
Butoconazole
Butoconazole (butoconazole nitrate; Femstat, Gynazole-1) is an imidazole azole antifungal, first approved in 1985, used as 2% intravaginal cream, including a single-dose bioadhesive formulation, for vulvovaginal candidiasis.
Cabotegravir
Cabotegravir (Vocabria, Apretude, Cabenuva) is an HIV-1 integrase strand transfer inhibitor from ViiV Healthcare, given as a 600 mg intramuscular injection every 2 months for PrEP and with rilpivirine for HIV treatment.
Candicidin
Candicidin, also known as levorin or ascosin (same major components), is a polyene aromatic heptaene antifungal antibiotic from Streptomyces griseus that binds ergosterol; formerly used vaginally against candidiasis.
CB06 (oral TLR8 agonist)
CB06 (development code CB06-036) is an oral small-molecule agonist of Toll-like receptor 8, developed by Shanghai Zhimeng Biopharma for chronic hepatitis B and licensed globally to GSK in December 2022.
Cenicriviroc
Cenicriviroc (CVC, TBR-652, formerly TAK-652) is an oral dual CCR2/CCR5 antagonist developed as an anti-HIV entry inhibitor and NASH antifibrotic; its phase 3 AURORA trial failed and COVID-19 trials showed no benefit.
Cepeginterferon alfa-2b
Cepeginterferon alfa-2b (Algeron, цепэгинтерферон альфа-2b) is a Russian pegylated interferon alfa-2b with a 20 kDa PEG, used with ribavirin for chronic hepatitis C; single-isomer, once-weekly subcutaneous dosing.
Chinin hydrochlorid
Chinin hydrochlorid (quinine hydrochloride, CAS 7549-43-1) is the hydrochloride salt of the cinchona alkaloid quinine, formulated mainly as 300 mg/mL parenteral solution for treating severe malaria by rate-controlled infusion.
Chlorproguanil
Chlorproguanil (Lapdap, with dapsone) is a biguanide antifolate antimalarial, a proguanil analog with an extra chlorine atom, developed at Liverpool as a cheap SP replacement and withdrawn in 2008 for G6PD-deficient hemolysis.
Ciclopirox
Ciclopirox, a hydroxypyridone topical antifungal (ATC D01AE14), treats skin and nail fungal infections via iron chelation, not ergosterol inhibition; sold as 0.77% cream, 1% shampoo, and 8% nail lacquer, with low resistance potential and investigational anticancer and antibacterial uses.
Cidofovir anhydrous
Cidofovir anhydrous (HPMPC, UNII 768M1V522C) is an acyclic phosphonate nucleotide antiviral, C8H14N3O6P, MW 279.19, marketed as Vistide; FDA-approved June 1996 for CMV retinitis in AIDS, dosed IV every other week with probenecid, dose-limited by nephrotoxicity.
Clevudine
Clevudine (L-FMAU; brands Levovir, Revovir) is a pyrimidine nucleoside analogue inhibiting HBV reverse transcriptase, approved in South Korea in 2006, notable for prolonged post-treatment suppression but limited by mitochondrial myopathy and resistance versus entecavir.
Clotrimazole
Clotrimazole (Canesten, Lotrimin) is a topical imidazole antifungal introduced by Bayer in 1969; it inhibits fungal CYP51/ergosterol synthesis and treats skin, oral, vaginal, and ear fungal infections, being less effective than fluconazole for oral candidiasis.
Coblopasvir hydrochloride
Coblopasvir hydrochloride (盐酸可洛派韦, brand name Kailiwei) is a Chinese-developed NS5A inhibitor, approved in February 2020 and taken once daily with sofosbuvir for 12 weeks to treat chronic hepatitis C.
Combined antiretroviral therapy
Combined antiretroviral therapy (cART), also called ART or formerly HAART, is the use of multiple antiretroviral drugs together to suppress HIV, cutting death rates by 50 to 80%.
COVID-19 Drug Treatment
COVID-19 drug treatment covers antivirals (Paxlovid, remdesivir, molnupiravir), dexamethasone and tocilizumab for severe disease, monoclonal antibodies, and disproven drugs like hydroxychloroquine, with treatment started within 5-7 days of symptoms.